Specialties: Medical Oncology
ClinicalInterests: He specializes in immunotherapy, molecular targeted drug therapy, chemotherapyof gastrointestinal tumors, head & neck squamous cell carcinoma, etc. Hehas extensive experience and expertise in the field of gastrointestinal andhead & neck medical oncology and translation research.
Experience:
2010-2014,Postdoctoral Fellow, Oncology, The University of Texas MD Anderson CancerCenter, Houston, TX, USA
2014-2020,Associate Professor, Associate Chief Physician, Deputy Director of Departmentof Biotherapy (Presiding over the department), The Fifth Affiliated Hospital ofSun Yat-sen University, Guangdong, China
2020-present,Chief Physician, Deputy Director of Department of Medical Oncology, GuangdongProvincial People’s Hospital, Guangdong, China
Education:
2003,Shandong University, Shandong, China, Bachelor, Clinical Medicine
2010,Sun Yat-sen University, Guangdong, China, Ph.D., Oncology
Awardsand Honors:
Guangdong Outstanding Young Medical Talent,Guangdong, China, 2018
Outstanding tutor ofEight-year medical education, Sun Yat-sen University, China, 2016
Abstract Achievement Award, 53th American Society of Hematology (ASH) meeting, San Diego, USA, 2011
Young Investigators Award, 20th Asia Pacific Cancer Conference, Tsukuba, Japan, 2009
Professionalmemberships: Immunotherapy Committee of ChineseSociety of Clinical Oncology, member, 2018-present
Publications:
1. Siyun Wang*, Haiqing Ma*, Yan Yan*, et al.cMET promotes metastasis and epithelial-mesenchymal transition in colorectalcarcinoma by repressing RKIP. J CellPhysiol. 2021;236(5):3963-3978.
2. Shuncong Wang*, Haiqing Ma*, Xuemin Li, et al.DNASE1L3 as an indicator of favorable survival in hepatocellular carcinomapatients following resection. Aging.2020Jan 24;12(2):1171-1185.
3. Cuiling Zhou*, Gang Che*, Xiaobin Zheng,…… Huanhuan Sun#, Haiqing Ma#.Expression and clinical significance of PD-L1 and c-Myc in non-small cell lungcancer. Journal of Cancer Research andClinical. 2019 Nov;145(11):2663-2674.
4. Haiyu Zhang*, Xiaofeng Pei*, XiangqiongMo, …… Huanhuan Sun#, HaiqingMa#. Incidence and survival changes in patients with esophagealadenocarcinoma during 1984-2013. BioMedResearch International. 2019 Dec 12; 2019:7431850.
5. Junlan Qiu*, Gang Che*, Fu Liu, …… Haiqing Ma#, Lin Feng#. The detection andclinical significance of peripheral regulatory CD4 + CD25 hi CD127 low T cellsin patients with non-small cell lung cancer. Clinical and Translational Oncology. 2019 Oct;21(10):1343-1347.
6. Bo Lin*, Haiqing Ma*, Maoguang Ma, etal. The incidence and survival analysis for anaplastic thyroid cancer: aSEER database analysis. American Journal of Translational Research. 2019 Sep15;11(9):5888-5896.
7. Gang Che*, Bingjiang Huang*, Zhinan Xie*,…… Huanhuan Sun#, Haiqing Ma#.Trends in incidence and survival in patients with melanoma, 1974-2013. American Journal of Cancer Research. 2019 Jul 1;9(7):1396-1414.
8. Li Zhong*, Dan Liao*, Meifang Zhang,...... Haiqing Ma#, TiebangKang#. YTHDF2 suppresses cell proliferation and growth viadestabilizing the EGFR mRNA in hepatocellular carcinoma. Cancer Letters. 2019 Feb 1;442;252-261.
9. Xiuling Zhou*, Xiangqiong Mo*, JunlanQiu*, ...... Zhong Lin#, HaiqingMa#. Chemotherapy combined with dendritic cell vaccine andcytokine-induced killer cells in the treatment of colorectal carcinoma: ameta-analysis. Cancer Management andResearch. 2018 Nov 5;10:5363-5372.
10. Yushi Li*, Huanhuan Sun*, Yan Yan*,...... Haiqing Ma#. Long-term survival rates of patients with stage III-IV hodgkin lymphomaaccording to age, sex, race, and socioeconomic status, 1984-2013. Oncologist. 2018 Nov;23(11):1328-1336.
11. Guanming Lu*, Jie Li*, Shuncong Wang*,...... Haiqing Ma#. Thefluctuating incidence, improved survival of patients with breast cancer, anddisparities by age, race, and socioeconomic status by decade, 1981-2010. Cancer Management and Research. 2018 Oct30;10:4899-4914.
12. Jinna Wu*, Huanhuan Sun*, ShuncongWang, ...... Guangwei Yang#, HaiqingMa#. Trend in relative survival in squamous cervical cancer bydecade from 1983 to 2012: a period analysis. Cancer Management and Research. 2018Sep 3;10:3177-3191.
13. Jinna Wu*, Huanhuan Sun*, Lewei Yang, ......Guangwei Yang#, Haiqing Ma#.Improved survival in ovarian cancer, with widening survival gaps of races andsocioeconomic status: a period analysis, 1983-2012. Journal of Cancer. 2018 Sep 8;9(19):3548-3556.
14. Jinna Wu*, Huanhuan Sun*, Jie Li,...... Changye Zou#, HaiqingMa#. Increased survival of patients aged 0-29 years withosteosarcoma: a period analysis, 1984-2013. CancerMedicine. 2018 Aug;7(8):3652-3661.
15. Fengze Sun*, Huanhuan Sun*, XiaobinZheng, ...... Zhibin Cheng#, HaiqingMa#. Angiotensin-converting enzyme inhibitors decrease theincidence of radiation-induced pneumonitis among lung cancer patients: asystematic review and meta-analysis . Journalof Cancer. 2018 May 5;9(12):2123-2131.
16. Haiqing Ma*, SaradhiMallampati*, Yue Lu, et al. The Sox4/Tcf7l1 axispromotes progression of BCR-ABL-positive acute lymphoblastic leukemia. Haematologica. 2014 Oct;99(10):1591-8.
17. Haiqing Ma*, Desheng Weng*,Yibing Chen, et al. Extensiveanalysis of D7S486 in primary gastric cancer supports TESTIN as a candidatetumor suppressor gene. Mol Cancer. 2010;9:190.
18. Haiqing Ma, Xiaoting Liang, Yibing Chen, et al. Decreased expression of BATF2 is associated witha poor prognosis in hepatocellular carcinoma. International Journal of Cancer. 2011;128(4):771-777.
19. Jin Wang*#, Bin Ya*, SongMeiLiu*,...... Ma Haiqing#. Transcriptomicand Functional Pathway Analysis of Human Cervical Carcinoma Cancer CellsResponse to Microtubule Inhibitor. JCancer. 2015;6(10):930-937.
20. Fengze Sun*, Huanhuan Sun*, XiangqiongMo, ...... Yonghui Su# and Haiqing Ma#. Increasedsurvival rates in gastric cancer, with a narrowing gender gap and wideningsocioeconomic status gap: A period analysis from 1984 to 2013. J Gastroenterol Hepatol. 2018;33(4):837-846.
21.Haiqing Ma*, Yaojun Zhang*, Qijing Wang*, et al. Therapeutic safety and effects of adjuvant autologousRetroNectin activated killer cell immunotherapy for patients with primaryhepatocellular carcinoma after radiofrequency ablation. Cancer Biol Ther. 2010;9(11):903-907.
22. Shuncong Wang*, Rongfeng Song*,Tiantian Sun, ...... Haiqing Ma#, Huanhuan Sun#. Survival changes inPatients with Synovial Sarcoma, 1983-2012. JCancer. 2017;8(10):1759-1768.
23. Huanhuan Sun*, Haiqing Ma*, Guobin Hong*, etal. Survival improvement in patients with pancreatic cancer by decade: aperiod analysis of the SEER database, 1981-2010. Sci Rep. 2014;4:6747.
24. HaiqingMa*, Huanhuan Sun*, Xiaoping Sun*. Survival improvement by decade ofpatients aged 0-14 years with acute lymphoblastic leukemia: a SEER analysis. Sci Rep. 2014;4:4227.
25. Rong Cai*, Rongfeng Song*, Pengfei Pang,...... Huanhuan Sun#, HaiqingMa#. Transcatheter arterial chemoembolization plus sorafenibversus transcatheter arterial chemoembolization alone to treat advancedhepatocellular carcinoma: a meta-analysis. BMC Cancer. 2017;17(1):714.
26. HaiqingMa*#, SaradhiMallampati*, Gang An*, et al. TargetedTherapy in Hematological Malignancies: From Basic Research to ClinicalPractice. Biomed Res Int. 2015;2015:157570.
27. Huakun Zhang*, Haiqing Ma*, Qijing Wang, etal. Analysis of loss of heterozygosity on chromosome 4q in hepatocellularcarcinoma using high-throughput SNP array. OncolRep. 2010;23(2):445-455.
